445 people with lasting facial redness from rosacea were randomly given oxymetazoline 1% cream or an identical cream without the drug, once a day for 29 days. More people on the active cream improved by at least two grades on both the doctor's and their own rating, held across 3, 6, 9 and 12 hours after applying. Digital photo analysis agreed. Two points are worth knowing: the drug narrows blood vessels, so it covers redness rather than treating what causes it, and only 2 of 445 people had redness rebound after stopping — a common worry with this class. Manufacturer-funded.
Baumann L, Goldberg DJ, Stein Gold L, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17(3):290-298.
Read the full study on PubMed ↗